FDA aims to strengthen cybersecurity of medical devices

The Food and Drug Administration (FDA) is working to strengthen the cybersecurity of medical devices in the wake of computer-hacking threats, according to a report by the Star Tribune.

According to the report, FDA staff members are examining companies’ “preparations for potential computer-hacking threats to devices that millions of Americans depend on.” The plans were recently detailed in an audit report by the U.S. Department of Health and Human Services’ Office of the Inspector General.

Under these suggested guidelines, the FDA will begin asking questions about a device’s cybersecurity during the device-approval process.

“The FDA has been ramping up its cyber enforcement in recent years, starting in 2013 with the formation of a ‘cybersecurity working group’ and the publication of rules in 2014 for how the FDA expects manufacturers to develop long-term plans for medical device cybersecurity,” the report read. “FDA guidelines say manufacturers should submit a cybersecurity hazard analysis with device applications and include plans for how to issue future software updates.”

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.